Xerion Ltd appoints Non-Executive Director
We are delighted to partner the Chairman Dr Andrew Monk of Xerion Limited to appoint a Non-Executive Director.
Congratulations to Jeff Sells, a qualified Chartered Accountant and graduate from the Harvard Business School's Executive Education Advanced Management Program AMP.
Currently at Sigma Healthcare Limited (ASX: SIG), Jeff leads the Retail Pharmacy customer business unit which is committed to bringing the community healthcare to every Australian, through health services delivered in pharmacies, and delivering vital medicines to any pharmacy in Australia within 24 hours.
Jeff is an experienced senior business leader in strategy, team development, finance, sales leadership, network and business development. Thriving off taking on new challenges to lead and build close-knit teams that work at sustainable improvement of business models, Jeff has worked across varied industries, including professional services, natural resources, pharmaceutical and retail. Furthermore, he has worked in various countries and cultures in Africa and Asia which has helped to develop an understanding of leading in cross-cultural settings.
Jeff's core experience is in corporate finance, investor relations, business planning, mergers & acquisitions, business development and sales management. He has made the transition from senior finance executive to leading business units that develop and execute strategic change.
Xerion Limited is an Australian-based specialty global pharmaceutical company focused on revolutionising standard of care in dermatology through the development of innovative therapies.
Foley Durham continues to partner with high growth companies in appointing NED's and c-suite executives gearing up for an IPO or those that are ASX listed.
Congratulations again to Jeff who will be valued contributor
in the successful implementation of the company’s growth plans.
Xerion Limited is an Australian-based specialty pharmaceutical company focused on revolutionising standard of care in dermatology through the development of innovative therapies.
Foley Durham continues to lead the way partnering with Chairman of Boards to appoint NED's of ASX listed companies and pre IPO businesses seeking diversity in board composition.
For a confidential discussion about your future NED opportunities or Board search, please contact Foley Durham Managing Director, Jason Foley BCom MAICD on +61 405 181 882